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Tp53 is an important tumor suppressor gene, which induces cell growth arrest or apoptosis when 
subjected to cytotoxic stimuli. Association has been reported between various cancers and p53 codon 
72 polymorphism. Our objective was to investigate the possible association between p53 at codon 72 
for Arg/Arg, Arg/Pro and Pro/Pro allele polymorphisms in blood samples from 187 prostate cancer 
patients and 185 controls in southwest Iran by nested-polymerase chain reaction (PCR) of p53 exon 4 
and digestion with BstUI restriction enzyme and the DNA fragments were then resolved by 
electrophoresis in 2% agarose gel. The frequencies of Arg/Arg, Arg/Pro and Pro/Pro genotypes were 
39.57% (74/187), 52.41% (98/187) and 8.02% (15/187), respectively, in the cases with prostate cancer, and 
27.03% (50/185), 60% (111/185) and 12.97% (24/185), respectively in the healthy controls. Statistically, 
analyzed and combined results showed there was a significant difference in the frequency of the 
Arg/Arg genotype and Arg allele between prostate cancer cases and control (p>0.001). These findings 
suggest that p53 Arg/Arg genotype could be a risk factor for the development of prostate cancer among 
patients in southwest Iran. 
 





The prostate gland is a male sex gland. Located below 
the urinary bladder, it is about the size of a walnut. The 
urethra, a tube that transports urine, passes through the 
prostate (Huang et al., 2004). Prostate cancer occurs 
when cells in the prostate gland grow out of control. 
Prostate cancer is the fifth most common cancer in the 
world and the second most common cancer among men 
(Zhu et al., 2010). There are often no early prostate 
cancer symptoms, but some men have urinary symptoms 
and discomfort. Some prostate cancers do not stay in the 
prostate, but spread to other parts of the body such as 
the bones and lymph nodes. This is called metastatic 
prostate cancer. Many studies indicate that environ-
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significant role in the etiology of this disease (Quinones et 
al., 2006). Given the multicausal etiology of prostate 
cancer, synergistic interactions among genetic and other 
risk factors might have significant effects on prostate 
cancer risk, especially gene-gene (G×G) and gene-
environment (G×E) interactions (Quinones et al., 2006 
However, for men who have a father or brother with 
prostate cancer, their risk is known to be higher. The risk 
is higher again if more than one member of your family 
has prostate cancer. 
 This cancer accounting for almost 11.7% of new 
cancer cases overall, constitutes 19% of cancers in 
developed countries and 5.3% in developing countries 
(Sadjadi et al., 2007).  
Prostate cancer also accounts for 33% of all newly 
diagnosed malignancies among men in the United 
States. According to the American Cancer Society, an 
estimated 220,900 men will be diagnosed with prostate 
cancer in 2003, and 28,900 men will die of it, making it 
the second most common cause of cancer death in men. 
In 2007, the estimated number of new cases affected by 
prostate cancer was 782600 with  254000  deaths  (Guan 
   




et al., 2006). More than 11,000 men are diagnosed with it 
and 2700 die of it in Australia each year. Prostate cancer 
is very age dependent, so that more than half of all new 
prostate cancers and over 80% of prostate cancer deaths 
occur in men over the age of 70 (Pietsch et al., 2006). 
p53 is the most commonly mutated gene in human 
cancers and more than 50% of human tumors contain 
inactivating mutations of p53 gene (Guan et al., 2006). 
The human p53 tumor suppressor gene is located on 
chromosome 17p13 and encodes a 53-kDa nuclear 
phosphoprotein, which plays a central role in many 
cellular processes such as cell-cycle control, DNA repair 
and apoptosis in prostate cancer. Mutations of this gene 
are frequently seen in both germ line and somatic forms 
(Zhu et al., 2010; Huang et al., 2004). The p53 protein is 
activated in response to various genotoxic and non-
genotoxic stimulus, triggering the expression of several 
genes that affect DNA repair (via the GADD45 pathway) 
and cell cycle arrest (via the p21 pathway). If repair fails, 
apoptosis is triggered (via the bax pathway), hence, the 
denomination of p53 as the ‘‘genome guardian’’ (Lima-
Ramos et al., 2008; Vazquez et al., 2010). 
The codon 72 polymorphism is located in exon 4 of the 
p53 gene, a region involving very few mutations. p53 
protein exhibits a common polymorphism at amino acid 
72, resulting in either a proline residue (CCC) or an 
arginine residue (CGC) (Guan et al., 2006; Cao et al., 
2009). Three genotypes occur: arginine homozygotes 
(Arg/Arg), proline homozygotes (Pro/Pro), and hetero-
zygotes (Pro/Arg). A guanine/cytosine variant at the 
second position of codon 72 on exon 4 leads to Arg72 or 
Pro72 protein variants with markedly altered primary 
structures and different biochemical functions. The 
current view is that the P53-Arg72 protein is more effec-
tive than the P53-Pro72 protein at inducing apoptosis and 
protecting cells from tumor development (Li et al., 2010; 
Huang et al., 2004).  
Most studies investigating potential risk factors for 
prostate cancer have been conducted in the West, with 
consistent demographic findings including older age, 
family history, African American race, and residence in a 
Western nation (Hosseini et al., 2009). The incidence of 
prostate cancer is much lower in Asian than Western 
populations and the disease and its risk factors have 
been less studied in the region, including Iran (Pourmand 
et al., 2007; Hosseini et al., 2009) . In the present study, 
we examined the genotype frequency of codon 72 in 
prostate cancer patients and determined the role of the 
p53 polymorphism in Southwest Iran using Nested-
polymerase chain reaction (PCR) and restriction fragment 




MATERIALS AND METHODS 
 
Patient and control populations 
 





cancer between 2009 and 2010 in the Chaharmahal Va Bakhtiari 
province located in Southwest Iran. A total of 187 male prostate 
cancer cases with ethical symptoms such as sudden need to 
urinate often at night; painful urination, etc., (median age: 61.46, 
range: 45 and 88 years) arose during the study period. Blood 
samples of 185 people (median age: 58.12, range: 43 and 87 
years) selected randomly from among clinical laboratories and were 





Total DNA was extracted from the blood samples using a DNA 
extraction kit (QIAGEN Ltd., Crawley, UK) according to the 
manufacturer’s procedure. The extracted DNA was stored at -20°C 
until needed for amplification. 
 
 
TP53 Arg72Pro genotyping analysis and gene amplification 
 
Analysis of TP53 Arg72Pro polymorphism was performed by 
Nested-PCR and PCR-RFLP. The primers used for one-step 
amplification were D1-F: 5′-GCT CTT TTC ACC CAT CTA CAG- 3′ 
and D2-R: 5′-TGA AGT CTC ATG GAA GCC AGC- 3′, while those 
used for two-step amplification were F2-F: 5′-TCC CCC TTG CCG 
TCC CAA- 3′ and R2-R: 5′-CGT GCA AGT CAC AGA CTT- 3′. 
Briefly, amplification reaction was carried out in a total volume of 25 
µL, consisting of 1 µg of template DNA, 1 µM of each primers, 2 
mM Mgcl2, 200 µM dNTP, 5 µL of 10 X PCR buffer and 1 U of Taq 
DNA polymerase (Roche applied science). PCR amplification was 
performed in a Mastercycler Gradiant (Eppendorf, Germany) with 
an initial denaturation step at 95°C for 5 min, then amplified for 30 
cycles of denaturation at 94°C for 1 min, annealing at 58°C for 1 
min, extension at 72°C 1 min and, final extension step at 72°C for 5 
min. Reaction mixture without DNA template was used as a 
negative control and that with known DNA template was used as a 
positive control, which yielded PCR products of expected results. 
Reaction mixtures were as aforementioned, except that 2.5 µL of 
product from the first step as template DNA and the second primers 





The PCR product was then analyzed by RFLP. The PCR product 
from second step digested overnight at 37°C with BstUI restriction 
enzyme (Fermentas, Germany), according to the manufacturer’s 
instructions. The results of enzymatic digestion were visualized in a 





Analysis of p53 gene polymorphism in prostate cancer cases was 
performed using the SPSS version 17.0 computer software (SPSS, 
Chicago, IL). 95% confidence intervals for the observed genotype 
frequencies were calculated. The Chi-squared test was used to 
establish whether the sample and control groups were in Hardy–
Weinberg equilibrium, and whether the proportions of the three p53 
codon 72 genotypes differed between the cases and control 
groups.  
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Figure 1. The PCR-RFLP analysss of p53 codon 72 after digestion with BstUI enzyme. Lane M 
is 100 bp DNA ladders (Fermentas, Germany), lane 1 is homozygote sample for Pro allele, lane 




Also standard error of mean allelic frequencies of p53 gene was 
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To test deviation from Hardy-Weinberg equilibrium, the following 



















The results were the 279 bp fragment of uncut PCR 
product representing homozygotes proline, two fragments 
of 160 and 119 bp representing homozygotes arginine, 
and three fragments 279, 160 and 119 bp representing 
heterozygotes (Arg/Pro) for codon 72. A representative 
Nested-PCR and RFLP pattern is depicted in Figure 1. 
The frequencies of the Arg/Arg, Arg/Pro, and Pro/Pro 
genotypes in the control group were 27.03, 60 and 
12.97% respectively. Among the 187 prostate cancer 
cases, 74 cases (39.57%) were homozygous for the Arg 
72 allele (Arg/Arg), 15 cases (8.02%) were homozygous 
for the Pro 72 allele (Pro/Pro) and 98 cases (52.41%) 
found in heterozygous (Arg/Pro). The distribution of the 
three different TP53 codon 72 genotypes (Arg/Arg, 
Arg/Pro, and Pro/Pro) in both groups (cases and controls) 
is presented in Table 1. 
 First, we compared the genotype frequencies between 
prostate cancer patients and normal controls, thus 
confirming the accumulation of Arg/Arg genotype in these 
patients (39.57% vs. 27.03%, P>0.001).  
Likewise, the distribution of the Pro allele variant 
between case and control groups was not statistically 
different (P>0.05). In the current study, the p-value is less 
than 0.05 (5%), so Arg/Arg genotype in prostate cancer 
patients is statistically significant. Comparison of the 
allele frequencies revealed an increase in the Arg allele 
among prostate cancer patients compared to controls 





The mutation of the p53 gene is one of the most frequent 
genetic changes found in human cancers such as 
cervical cancer, breast cancer, colorectal and prostate 
cancer.  In   addition  to  mutations  that  arise  during  the  
   




Table 1. Distribution of p53 codon 72 polymorphism genotypes among prostate cancer cases and controls 
in Southwest Iran. 
 
Genotype 
Cases (N = 187) Controls (N = 185) 
P-Value 
N % N % 
Arg/Arg        74 39.57 50 27.03 >0.001 
Arg/Pro        98 52.41 111 60 >0.05 




Table 2. Allele frequencies of TP53 codon 72 among prostate cancer cases and controls in Southwest 
Iran.  
Allele 
Cases frequency Controls frequency 
P-Value 
N % N % 
Arg 123 65.77 106 57.03 >0.001 




growth and development of individuals (sporadic 
mutations), there are forms of cancer associated with the 
inheritance of a damaged version of p53 (Pezeshki et al., 
2006; Pietsch et al., 2006). The p53 gene is known to 
exhibit distinct mutational patterns in various cancer 
types. The frequency of p53 mutations in p53 in prostate 
cancer is lower than in other carcinomas, such as 
esophageal carcinoma and oral squamous cell 
carcinoma, in which the frequency of p53-specific 
antibodies in patients’ serum is high (Kubota et al., 2008). 
The proline/arginine substitution at codon 72 represents a 
common amino acid polymorphism in the p53 gene, the 
functional significance of which is unknown (Onrat et al., 
2009). This may be due to the production of a mutant p53 
protein that is not capable of inducing apoptosis in 
response to toxic environmental stimuli (Lung et al., 
2004). 
Few studies have been conducted on the risk factors 
for prostate cancer in the Iranian context. The incidence 
of prostate cancer in Iran is very low as compared to the 
Western countries (Pourmand et al., 2007). This can 
partly be explained by lack of nationwide screening 
program, younger age structure and quality of cancer 
registration system in Iran. The findings of this study 
showed that prostate cancer is one of the most common 
cancers in Southwest Iran among males (Hosseini et al., 
2009; Marjani and Kabir, 2008). In the present study, we 
also evaluated the role of the TP53 Arg72Pro 
polymorphism in the prostate patients. The evaluation 
showed a statistically significant difference in overall 
survival among the individuals with different genotypes. 
The frequencies of p53 codon 72 genotype in prostate 
cancer cases revealed 74 cases (39.57%) arginine 
homozygotes (Arg/Arg), 15 cases (8.02%) proline 
homozygotes (Pro/Pro) and 98 cases (52.41%) 
arginine/proline heterozygotes (Arg/Pro). Frequencies of 
Arg/Arg, Arg/Pro and Pro/Pro in p53 among controls were 
50 (27.03%), 111 (60%)  and  24  (12.97%),  respectively.  
In the current study, the frequency of p53 codon 72 
genotypes among the controls and patients closely 
conformed to Hardy-Weinberg equilibrium and we found 
significant differences in the genotype or allele 
frequencies between the patients and the control groups. 
Moreover, the results show increases in the Arg/Arg 
genotype and a decrease in Pro/Pro genotype among 
patients and an increase in the Arg allele. Many studies 
were performed about p53 codon 72 polymorphisms and 
its correlation to cancer diseases in patients in Iran and 
other places. Hosseini et al. (2009) showed that several 
recognized risk factors for prostate cancer contributes 
evidence to the discussions of other hypothesized risk 
factors, and points to potentially new factors in Iran. In 
Golestan, north province of Iran harbor, a rather 
incidence for prostate cancer (in age 80 to 84), 
comparable to the lower incidence rate reported in the 
world was reported (Marjani and Kabir, 2008).  
In prostate cancer, studies of p53 codon 72 
polymorphism have shown different results in different 
populations. The findings of Huang et al. (2004) showed 
that Arg/Arg genotype was associated with BPH risk in 
those with large prostate volumes (Huang et al., 2004). A 
number of studies have failed to demonstrate the 
association between the p53 codon 72 polymorphism 
prostate cancers. For example, Henner et al. (2001) 
showed the Pro/Pro genotype was associated with a 
markedly lower risk of prostate cancer and men with the 
p53 codon 72 Pro/Pro genotypes appear to be at reduced 
risk of prostate cancer. Suzuki et al. (2003) showed that 
Pro/Pro genotype of p53 codon 72 played a role in 
prostate cancer susceptibility in a Japanese population. 
However, the Pro allele did not appear to worsen such 
clinical parameters as clinical stage or pathological 
grade. The results of the study of Lima-Ramos et al. 
(2008) for role of TP53 Arg72Pro polymorphism in a large 
series of Portuguese glioma tumors showed no 
association with glioma susceptibility  or  overall  survival,  





except for patients submitted to adjuvant therapy. The 
findings of Cao et al. (2009) also indicated that p53 Pro72 
variant is associated with an increased risk for colorectal 
cancer in the Korean population. In addition, the p53 
codon 72 polymorphism associations with bladder cancer 
and that genotypic distribution of this polymorphism were 
showed by Li et al. (2010) in China. In agreement with 
prior studies on breast, colorectal and prostate cancer in 
Iran, we found significant differences in the genotype or 
allele frequencies between the patients and the control 
groups (Mojtahedi et al., 2010). More also, the allele and 
genotype frequencies of the p53 codon 72 Arg/Arg 
polymorphism in stomach, colorectal adenocarcinoma, 
breast and prostate cancer patients compared to the 
healthy individuals from the population of Southern Iran 
showed significant differences in the genotype or allele 
frequencies between the patients and the control groups 
(Khadang et al., 2007).  
In conclusion, the findings of present study suggested 
that Arg/Arg genotype could be a risk factor for the 
development of prostate enlargement and cancer  , and 
p53Arg72 protein may be correlated with possible 
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